急性呼吸窘迫综合征亚表型与辛伐他汀差异反应:一项随机对照试验的二次分析
HARP-2是一项在英国和爱尔兰40家医院ICU开展的多中心随机对照试验,纳入540例ARDS患者,随机接受辛伐他汀80 mg或安慰剂。本二次分析对539例患者基线数据进行潜类别分析,识别出低炎症型(353例,65%)和高炎症型(186例,35%)两个亚表型。高炎症型患者无呼吸机天数更少(中位2天 vs 18天)、无肺外器官衰竭天数更少(15天 vs 27天)、28天死亡率更高(39% vs 17%)。尽管总体分析未显示辛伐他汀与安慰剂在28天生存上有差异,但按治疗和亚表型分层后生存差异显著(p<0.0001),高炎症型中辛伐他汀组28天生存率显著高于安慰剂组(p=0.008),90天生存呈相似模式。
要点
- HARP-2二次分析识别出两个ARDS亚表型:低炎症型353例(65%)和高炎症型186例(35%),两亚表型临床与生物学特征与既往研究相似。
- 高炎症型患者预后更差:无呼吸机天数中位2天 vs 低炎症型18天,无肺外器官衰竭天数15天 vs 27天,28天死亡率39% vs 17%(均p<0.0001)。
- 总体HARP-2未发现辛伐他汀与安慰剂在28天生存上有差异,但按治疗和亚表型分层后生存差异显著(p<0.0001)。
- 高炎症型亚表型中,辛伐他汀组28天生存率显著高于安慰剂组(p=0.008),90天生存呈相似模式。
- 作者认为这些发现支持在重症临床试验中进一步追求预测性富集策略。
适用人群与场景
- HARP-2纳入在英国和爱尔兰40家医院综合ICU中、ARDS起病48小时内患者,随机接受辛伐他汀80 mg或安慰剂。
- 本二次分析纳入539例有可用数据的患者(1例撤回数据使用同意)。
诊断标准与关键阈值
- 采用潜类别分析对基线数据(不考虑结局)识别亚表型,两类别模型优于单类别模型(p<0.0001),增加类别未改善模型拟合。
- 低炎症型亚表型353例(65%),高炎症型亚表型186例(35%)。
研究设计与关键结果
- HARP-2为多中心随机对照试验,辛伐他汀80 mg vs 安慰剂,纳入540例,分析539例。
- 高炎症型 vs 低炎症型:无呼吸机天数中位2天(IQR 0-17)vs 18天(IQR 0-23),p<0.0001。
- 高炎症型 vs 低炎症型:无肺外器官衰竭天数15天(0-25)vs 27天(21-28),p<0.0001。
- 高炎症型 vs 低炎症型:28天死亡率39%(73例)vs 17%(59例),p<0.0001。
- 总体辛伐他汀与安慰剂28天生存无差异,但按治疗和亚表型分层后生存差异显著(p<0.0001)。
- 高炎症型亚表型中,辛伐他汀组28天生存率显著高于安慰剂组(p=0.008),90天生存呈相似模式。
证据类型、等级与局限
- 证据类型:多中心随机对照试验的二次分析。
- 作者结论:两个ARDS亚表型具有不同临床和生物学特征及不同结局,高炎症型亚表型接受辛伐他汀较安慰剂生存改善,支持进一步追求预测性富集策略。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该二次分析提示,高炎症型ARDS亚表型患者接受辛伐他汀80 mg可能与28天生存改善相关(p=0.008),低炎症型未见此差异。
- 作者认为这些发现支持在重症临床试验中进一步追求预测性富集策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Precision medicine approaches that target patients on the basis of disease subtype have transformed treatment approaches to cancer, asthma, and other heterogeneous syndromes. Two distinct subphenotypes of acute respiratory distress syndrome (ARDS) have been identified in three US-based clinical trials, and these subphenotypes respond differently to positive end-expiratory pressure and fluid management. We aimed to investigate whether these subphenotypes exist in non-US patient populations and respond differently to pharmacotherapies.
METHODS: HARP-2 was a multicentre, randomised controlled trial of simvastatin (80 mg) versus placebo done in general intensive care units (ICUs) at 40 hospitals in the UK and Ireland within 48 h of onset of ARDS. The primary outcome was ventilator-free days, and secondary outcomes included non-pulmonary organ failure-free days and mortality. In a secondary analysis of HARP-2, we applied latent class analysis to baseline data without consideration of outcomes to identify subphenotypes, and we compared clinical outcomes across subphenotypes and treatment groups.
FINDINGS: 540 patients were recruited to HARP-2. One patient withdrew consent for the use of their data, so data from 539 patients were analysed. In our secondary analysis, a two-class (two subphenotype) model was an improvement over a one-class model (p<0·0001), with 353 (65%) patients in the hypoinflammatory subphenotype group and 186 (35%) in the hyperinflammatory subphenotype group. Additional classes did not improve model fit. Clinical and biological characteristics of the two subphenotypes were similar to previous studies. Patients with the hyperinflammatory subphenotype had fewer ventilator-free days (median 2 days [IQR 0-17] vs 18 [IQR 0-23]; p<0·0001), fewer non-pulmonary organ failure-free days (15 [0-25] vs 27 [21-28]; p<0·0001), and higher 28-day mortality (73 [39%] vs 59 [17%]; p<0·0001) than did those with the hypoinflammatory subphenotype. Although HARP-2 found no difference in 28-day survival between placebo and simvastatin, significantly different survival was identified across patients stratified by treatment and subphenotype (p<0·0001). Specifically, within the hyperinflammatory subphenotype, patients treated with simvastatin had significantly higher 28-day survival than did those given placebo (p=0·008). A similar pattern was observed for 90-day survival.
INTERPRETATION: Two subphenotypes of ARDS were identified in the HARP-2 cohort, with distinct clinical and biological features and disparate clinical outcomes. The hyperinflammatory subphenotype had improved survival with simvastatin compared with placebo. These findings support further pursuit of predictive enrichment strategies in critical care clinical trials.
FUNDING: UK Efficacy and Mechanism Evaluation Programme and National Institutes of Health.
参考来源
- Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018. PMID: 30078618. doi:10.1016/S2213-2600(18)30177-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。